RxDoctor Payments Data

Venkataranga Nallapareddygari, MD

Family Medicine · East Brunswick, NJNPI 1518257856

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 1 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Every reported general payment came from a single manufacturer, Pfizer. That places this record below the midpoint for family medicine clinicians in NJ, where the typical reported total is $394.

$15in general payments, 2019–2025

Across 1 payment — averaging $14.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$15
$131,589in research payments, 2019–2025

Across 7 payments — averaging $18,798 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • C. R. Bard, Inc. & Subsidiaries$115K
  • Verona Pharma, Inc.$17K

What the payments were for

  • Food & beverage$15100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Pfizer1$15

How this compares

$15 in reported general payments places this provider in the 0th percentile of 2,084 family medicine providers in New Jersey.

See all family medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$75,611
Medicare patients
409
Services billed
437

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban16$4,426
Divalproex Sodium44$1,743
Naltrexone Hcl12$772
Memantine Hcl11$560
Atorvastatin Calcium22$435
Quetiapine Fumarate15$406
Mirtazapine18$351
Donepezil Hcl20$274
Propranolol Hcl11$233
ClopidogrelClopidogrel Bisulfate11$215
Trazodone Hcl21$180
Levothyroxine Sodium13$179
Tamsulosin Hcl13$170
Gabapentin15$164
Pantoprazole Sodium11$127

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$15$4,42616 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 0th percentile of 2,084 family medicine providers in New Jersey.

Other family medicine in East Brunswick

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →